Europe's new investment firm says it's on a mission to lift up the continent's 'underexploited' science

Nicole DeFeudis

Editor

Like many, Alexandre Mouradian saw the Covid-19 pandemic as a wake-up call. More disease emergencies are coming, he said, and he wanted to do something …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Europe's new investment firm says it's on a mission to lift up the continent's 'underexploited' science

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Eu­rope's new in­vest­ment firm says it's on a mis­sion to lift up the con­ti­nen­t's 'un­der­ex­ploit­ed' sci­ence

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Europe's new investment firm says it's on a mission to lift up the continent's 'underexploited' science